Skip to main content
    P

    Pliant Therapeutics Inc (PLRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.66
    -0.03 (-4.76%)

    Market Cap: $42.97M

    Last updated: Nov 17, 2026 at 4:06 PM ET

    Pliant Therapeutics Inc (PLRX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Pliant Therapeutics (PLRX) has a market cap of $42.97M and an enterprise value of $16.40M. Revenue fell 100.00% over the last 12 months from the 12 months before. It holds $26.57M more cash than debt, 61.83% of its market cap.

    Total Valuation

    Enterprise value is 61.83% below the market cap, as cash exceeds debt.

    Market Cap$42.97M
    Enterprise Value$16.40M
    Latest price (Nov 17, 2026)$0.66

    Key Dates

    The next earnings report is expected on Mar 9, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 9, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.04% in the quarter ended Sep 30, 2026 and grew 0.99% a year over 2 years.

    Shares Outstanding61.94M
    Shares Change (YoY)+0.88%
    Shares Change (QoQ)+0.04%
    Share Count Growth (2Y CAGR)+0.99%

    Price Statistics

    The stock is down 60.70% over 52 weeks and trades 31.25% below its 50-day average.

    Beta (1Y)0.90
    52-Week Change-60.70%
    1-Month Change-26.54%
    3-Month Change-43.57%
    6-Month Change-42.59%
    5-Year Change-94.61%
    Total Return (1Y)-60.70%
    Total Return (3Y CAGR)-64.02%
    Total Return (5Y CAGR)-46.96%
    Max Drawdown (1Y)-59.99%
    Max Drawdown (3Y)-96.63%
    Sharpe Ratio (1Y)-1.80
    Correlation with SPY (1Y)0.26
    50-Day Average$0.96
    200-Day Average$1.13
    52-Week Range$0.66 to $1.67
    RSI (14 Days)18.9
    Average Volume (20 Days)377.81K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 8.05x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio8.05x
    Quick Ratio8.05x
    Debt / Equity0.00x

    Returns and Efficiency

    ROE (5Y Average)-54.77%
    ROA (5Y Average)-45.99%

    Scores

    PLRX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$365.00K
    Operating Income-$94.95M
    Pretax Income-$90.36M
    Net Income-$90.36M
    Reported EPS (TTM)-$1.42

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 74.54% of the $169.88M in total assets.

    Cash and Equivalents$26.57M
    Total Debt$0
    Net Cash$26.57M
    Net Cash Per Share$0.43
    Working Capital$126.29M
    Shareholder Equity$126.63M
    Book Value Per Share$2.04
    Total Assets$169.88M
    Total Liabilities$43.24M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$66.79M
    FCF Per Share-$1.08
    Depreciation and Amortization$1.68M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-38.88%
    Tangible Book Per Share Growth (2Y CAGR)-38.88%

    Revenue and profit by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About PLRX

    What is PLRX's market cap?

    Pliant Therapeutics has a market cap of $42.97M. Its enterprise value, which adds debt and subtracts cash, is $16.40M.

    How many shares of PLRX are outstanding?

    Pliant Therapeutics has 61.94M shares outstanding. The count is up 0.88% from a year earlier.

    Does PLRX pay a dividend?

    No. Pliant Therapeutics does not pay a dividend.

    How much debt does PLRX have?

    Pliant Therapeutics has $0 of total debt and $26.57M of cash and equivalents, a net cash position of $26.57M.